KAEDI and Kactus Biosystems reached a strategic cooperation

KAEDI and Kactus Biosystems reached a strategic cooperation

  On June 30, 2023, Kactus Biosystems (Shanghai) Co., Ltd. (hereinafter referred to as "Kactus Biosystems") and Nanjing KAEDI Technology Co., Ltd. (hereinafter referred to as "KAEDI") announced that they have reached a strategic cooperation agreement and signed a cooperation agreement in Nanjing. The agreement stipulates that the two parties will carry out various commercial cooperation based on the main business of each party, including but not limited to the cooperation of "overseas business promotion of synthetic biology products".

Left: Mr. Wang Gang, founder and CEO of Kactus Biosystems; Right: Mr. Dai Hongjiu, Founder, Chairman and CEO of KAEDI.

Mr. Wang Gang, founder and CEO of Kactus Biosystems, said
“We are delighted to enter into a strategic partnership with KAEDI. KAEDI has a number of CAR-T pipelines, all of which are world-leading and domestic leading Class 1 new drugs. The high-quality protein products produced by Kactus Biosystems under strict quality control can effectively help the research and development and application of cell therapy drugs. The deepening cooperation between the two parties will condense the advantages of a complete industrial chain of upstream and downstream collaborative progress, further promote the process of immunotherapy, and empower the development and industrialization of cell therapy drugs.”
 
Founder, Chairman and CEO of KAEDI
Mr. Dai Hongjiu said
“We are very pleased to enter into a strategic partnership with Kactus Biosystems. The rapid development of Kactus Biosystems is very prominent in the industry, and in just 5 years, Kactus Biosystems has grown into a well-known supplier of upstream protease raw materials. KAEDI has successfully developed a number of CAR-T first-class new drug R&D pipelines for malignant solid tumors, and the strategic cooperation between the two parties will complement each other's resource advantages and achieve the effectiveness of “1+1>2”, helping KAEDI to rapidly advance the R&D pipeline layout, thereby helping the R&D and industrialization process of cell therapy drugs.”
 
 
About | Kactus Biosystems
Founded in early 2018, Kactus Biosystems is a protease raw material company focusing on the upstream field of biological drugs and driven by independent innovation. Relying on the unique protein R&D platform SAMS^TM, Kactus Biosystems entered the antibody drug market from the field of difficult transmembrane proteins to solve the unmet market demand.
 
In the field of gene therapy, Kactus Biosystems provides localized GMP-grade Cas9 enzymes that can meet the clinical needs of gene editing, while Kactus Biosystems provides GMP-grade totipotent nucleases for AAV and vaccine industries, cytokines for cell therapy and raw enzymes for mRNA vaccine production, and several products have completed FDA DMF filing. The GMP products of Kactus Biosystems are developed and verified in strict accordance with the pharmacopoeia for testing methodology, equipped with MES digital production management system, and the products have good batch-to-batch stability and consistency, which meets the declaration requirements.
 
With a technical and professional team of nearly 250 people, the main operation location is located in the R&D and production center of Shanghai Pujiang Caohejing Development Zone and the tens of thousands of square meters of GMP-grade protease industrialization base in Lingang New Area, and has established overseas market commercial operation and logistics centers in Boston, USA.
 
About | KAEDI
KAEDI is a clinical-stage drug discovery and development company dedicated to developing novel cell drugs with unmet clinical needs in patients with solid tumors using a leading synthetic biology technology platform. Relying on KD-SmCAR™ and KD-ScCAR™, the company's independent CAR library screening platform, and KD-ScCAR™, a dual-targeted CAR development platform. KAEDI has successfully developed a number of new cell drug pipelines for solid tumors, including next-generation autologous and allogeneic CAR-T/CAR-NK pipelines. At present, more than 30 CAR-related patents have been declared and 15 patents have been authorized, among which the core pipeline KD-025, KD-496 and other patents are authorized for the first time in China and the United States. The product development results of KD-025 CAR-T targeting NKG2DL for liver cancer, colorectal cancer and glioma have been published in the international authoritative journal "Journal for ImmunoTherapy of Cancer", "Cancer Immunology Research" and the American annual cancer clinical meeting ASCO. The KD-025 CAR-T IIT clinical trial carried out in a well-known clinical center in China has completed a number of low-dose administrations without obvious toxic side reactions, and the product is safe and effective, and it is the first domestic KEDI is headquartered in Nanjing, China. For more information, please visit the official website of Nanjing KAEDI Technology Co., Ltd.:targeting CAR-T (KD-025) cells targeting NKG2DL solid tumors. The company that IND applied for CDE clinical approval is currently negotiating with a number of partners to start the first clinical phase of KD-025 registration, and at the same time, the company's core product KD-496 has entered the IIT clinical stage as the world's first new dual-targeted CAR-T cell injection. In addition, KAEDI is promoting the layout of the next generation allogeneic universal CAR-T/CAR-NK, and is expected to build KAEDI into a world-renowned solid tumor cell therapy company in the near future. The company has built a 3,000 square meters GMP cell drug R&D and production center, completed nearly 100 million yuan of financing, and is carrying out B round financing, At the same time, the company is rapidly advancing the development and commercialization of synthetic biology products through strategic cooperation.